{"id":"W4387135575","doi":"10.1136/ijgc-2023-esgo.899","title":"#1120 Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour BRCA1/2 mutation: results from the DUO-O/ENGOT-Ov46/AGO-OVAR 23/GOG-3025 trial","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Shota Rustaveli National Science Foundation; National Science Foundation","keywords":"Bevacizumab; Medicine; Carboplatin; Oncology; Internal medicine; Olaparib; Progression-free survival; Clinical endpoint; Urology; Ovarian cancer; Surgery; Cancer; Chemotherapy; Randomized controlled trial; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006473329,0.0007577022,0.001518632,0.000181396,0.0002008965,0.0009019872,0.0004303784,0.0005756741,0.004597157],"category_scores_gemma":[0.0006041644,0.0003156851,0.00111019,0.0002857734,0.0003853971,0.0007424916,0.0002346057,0.00225919,0.0009606425],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007252314,"about_ca_system_score_gemma":0.0006580957,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001836587,"about_ca_topic_score_gemma":0.007117603,"domain_scores_codex":[0.9998067,0.00007445111,0.00001255967,0.00004592082,0.00001887549,0.00004154975],"domain_scores_gemma":[0.9998091,0.00004011384,0.00003659212,0.00001637291,0.00001018771,0.00008774738],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7419187,0.004975181,0.006377472,0.001662123,0.004023956,0.0001761657,0.0001422023,0.002114845,0.01349884,0.0008859839,0.0128807,0.2113438],"study_design_scores_gemma":[0.8729165,0.08985554,0.01988166,0.0001825163,0.001920676,0.0003898921,0.00008382802,0.002268736,0.001647768,0.0008653401,0.009941883,0.00004568564],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9730891,0.01260765,0.0005857702,0.001589431,0.0006019406,0.000706901,0.002317019,0.0001939886,0.008308104],"genre_scores_gemma":[0.9804775,0.005147856,0.001120821,0.001818817,0.0002796281,0.0004241382,0.003722274,0.00004664603,0.006962392],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004597157,"threshold_uncertainty_score":0.01537901,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02467141838185468,"score_gpt":0.3167521971842686,"score_spread":0.2920807788024139,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}